Salvatore Tafuto
Elite in Neuroendocrine Tumor

Salvatore Tafuto

Naples, IT 
Elite in Neuroendocrine Tumor
Naples, IT 
OverviewLocationsClinical Research

Overview

Salvatore Tafuto practices in Naples, Italy. Mr. Tafuto is rated as an Elite expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Adult Soft Tissue Sarcoma, Hepato-Pancreato-Biliary Surgery, and Endoscopy.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 47 articles and participated in 1 clinical trial in the study of Neuroendocrine Tumor.

Gender
Male

Locations

Naples, Italy
Other Locations
Milan, Italy
Grazie, Italy
Pozzuoli, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients with GEP-NET
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients with GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: CAM2029, Octreotide LAR, Lanreotide ATG
Study Phase: Phase 3
View 2 Less Clinical Trials

93 Total Publications

Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors.
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors.
Journal: Frontiers in endocrinology
Published: August 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tafuto's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile